UNSPSC 51181623: Elcatonin

This classification denotes an antithyroid agent with the molecular formula C148H244N42O47, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W0CMS474JK, chemically known as1,7-Dicarbacalcitonin, 1-butanoic acid-26-L-aspartic acid-27-L-valine-29-L-alanine- but generally known as Elcatonin, which bears US NIH Compound Identifier 16129700. European Medicines Agency schedules Methylthiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06479MIG.

Elcatonin is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule elcatonin under HS 29371900 and SITC 54154. As of Q4 2014, ELCATONIN remains the US FDA Preferred Term for this commodity. Elcatonin bears US NLM identifiers UMLS ID C0115656 and NCI Concept Code C96281.

UNSPSC 51181623 Elcatonin, a Commodity code, addresses a narrow pharmaceutical product line. State and local governments procure elcatonin — a synthetic hormone used primarily to treat osteoporosis and related bone disorders — through health departments, correctional facilities, public hospitals, and institutional care providers. The code captures procurement of this specific therapeutic agent for patient administration within public healthcare systems, correctional medical units, and long-term care facilities operated or purchased by state and local bodies. Issuing bodies are predominantly state health departments, county hospital systems, and municipal public-health agencies that maintain formularies and manage pharmaceutical inventory for their patient populations.

The source provided contains no records of recent state and local contract opportunities under this code. Without current solicitation activity to reference, geographic concentration and representative recent procurements cannot be characterized. Elcatonin represents a specialized pharmaceutical commodity with limited procurement velocity compared to broader drug categories; activity under this code may be episodic, driven by formulary updates or institutional bid cycles rather than continuous open-market competition.